Skip to main content

Find Clinical Trials

Home
Conditions
Hepatitis C, Chronic

Clinical trial condition

Hepatitis C, Chronic

Explore clinical trials studying Hepatitis C, Chronic. Study availability and eligibility vary by location and protocol.

314 public trials 2 recruiting studies

Refine in advanced search Browse all conditions

Hepatitis C, Chronic trial results

Completed

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

NCT00869661

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Birmingham, Alabama, United States

La Jolla, California, United States

Sacramento, California, United States

San Diego, California, United States

View all 66 locations

View Trial Details

Completed

A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C

NCT01903954

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Not specified

View Trial Details

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.

NCT00475072

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Mexico City, Mexico

View Trial Details

Completed

HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)

NCT02806505

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Graz, Austria

Vienna, Austria

Brasília, Brazil

Porto Alegre, Brazil

View all 22 locations

View Trial Details

Completed

A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection

NCT01846832

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +15 more
Locations: Linz, Austria

Vienna, Austria

Brussels, Belgium

Edegem, Belgium

View all 20 locations

View Trial Details

Completed

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

NCT01399619

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: 1220.19.0045 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States

1220.19.0007 Boehringer Ingelheim Investigational Site Palm Springs, California, United States

1220.19.0031 Boehringer Ingelheim Investigational Site San Francisco, California, United States

1220.19.0005 Boehringer Ingelheim Investigational Site Washington D.C., District of Columbia, United States

View all 71 locations

View Trial Details

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

NCT01358864

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: 1220.7.0091 Boehringer Ingelheim Investigational Site North Little Rock, Arkansas, United States

1220.7.0082 Boehringer Ingelheim Investigational Site Englewood, Colorado, United States

1220.7.0095 Boehringer Ingelheim Investigational Site Palm Harbor, Florida, United States

1220.7.0039 Boehringer Ingelheim Investigational Site Columbus, Georgia, United States

View all 116 locations

View Trial Details

Completed

Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection

NCT02716779

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Berlin, Germany

Frankfurt am Main, Germany

Frankfurt am Main, Germany

Hanover, Germany

View Trial Details

Completed

Telaprevir Open-Label Study in Co-Infected Patients

NCT01500616

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +15 more
Locations: Antwerp, Belgium

Brussels, Belgium

Charleroi, Belgium

Ghent, Belgium

View all 29 locations

View Trial Details

Completed

Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus

NCT02761629

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Campinas, Brazil

Florianópolis, Brazil

Itajaí, Brazil

Juiz de Fora, Brazil

View all 17 locations

View Trial Details